A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

Condition:   Biliary Tract Cancer Interventions:   Drug: Nivolumab;   Drug: DKN-01 Sponsors:   Massachusetts General Hospital;   Bristol-Myers Squibb;   Leap Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials